Famciclovir 250 mg Tablet

Adult dose

1. Treatment of herpes zoster Adults: Administer 250 mg of famciclovir per dose orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of initial genital herpes infection Adults: Administer 250 mg of this drug per dose orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes infection Adults: Administer 125 mg of this drug per dose orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this drug per dose orally twice daily. Discontinue treatment periodically every 6～12 months to assess any changes in the natural course of the disease. 5. Patients with renal impairment: Since creatinine clearance of this drug is reduced in patients with renal impairment, dose adjustment should be made with care. The dosage for these patients is as follows. 1) Treatment of herpes zoster and initial genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 250 mg per dose once daily 2) Treatment of acute recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg per dose twice daily 10～29: 125 mg per dose once daily 3) Suppression of recurrent genital herpes infection: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg per dose twice daily 10～29: 125 mg per dose twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula: Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into account. A 4-hour hemodialysis session reduces the plasma concentration of this drug by approximately 75%; therefore, administer this drug immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, a clear recommended dose has not been established.

This medication should not be administered to certain patients. For instance, patients who have an allergy to this drug or its components, lactose intolerance, or inherited lactose metabolic disorders should not take this medication. Additionally, patients allergic to soybean oil, soy, peanut, etc. should also take caution. Patients with poor kidney function or issues with fat metabolism should be treated with this medication carefully. In particular, patients with hyperlipidemia, diabetic dyslipidemia, or pancreatitis need to be cautious when using this medication. When taking this medicine, symptoms like headache, nausea, vomiting, abdominal pain, and diarrhea can commonly occur. Occasionally, blood-related abnormalities such as thrombocytopenia or leukopenia have also been reported. Additionally, mental and nervous system symptoms like dizziness, drowsiness, confusion, and hallucinations may occur, so caution is advised. Liver function abnormalities, skin rashes, itching, and, rarely, severe skin reactions could also occur. In patients with poor kidney function, acute renal failure has been rarely reported, so monitoring kidney status is important. This medication cannot cure genital herpes; therefore, it is essential to avoid sexual contact and maintain safe sexual relations during treatment. If recurrence symptoms appear, treatment should be started immediately. It does not significantly affect driving or machine operation abilities, but caution should be taken if dizziness or drowsiness occur. Patients with mild to moderate liver dysfunction usually do not require dose adjustment; however, safety in severe liver impairment is not well established, so caution is needed. While this medication has a low potential for drug interactions, when taken with certain medications, blood concentration changes or toxicity potential should be monitored. Women who are pregnant or breastfeeding should use this medication with caution, and women of childbearing potential should use it only when necessary. Safety for children under 18 has not been established, so it is advisable not to use it in this population. Older adults usually do not require dose adjustments, but dosage should be adjusted in cases of impaired kidney function. In case of overdose, appropriate treatment should be administered, and if necessary, hemodialysis can be performed to reduce drug concentration. This medication should be stored in a sealed container as it is sensitive to air or moisture. Additionally, it is recommended to store it in a cool, dry place below 30 degrees Celsius.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is also advisable to store it in a cool, dry place below 30 degrees Celsius.

Appearance

White, round, film-coated tablets

Package unit

21 tablets (7 tablets/PTP x 3)